Market Place
Sourcing Support
Sun Pharma, Philogen Enter Exclusive Licensing Pact For Firbomun
30 Sep 2024 //
ECONOMICTIMES
Philogen, Sun Pharma announce EMA validates Marketing Authorization Application
04 Jul 2024 //
PHARMABIZ
Philogen and Sun Pharma seek EMA approval for melanoma therapy
04 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Philogen provides update on PIII trial investigating Onfekafusp alfa
20 Feb 2024 //
GLOBENEWSWIRE
Philogen announces receipt of GMP for its new Production facility in Rosia
05 Dec 2023 //
GLOBENEWSWIRE
Philochem & Blue Earth Announce Three Patients Imaged in Ph 1 of 68Ga-OncoFAP
04 Dec 2023 //
GLOBENEWSWIRE
Nidlegy Phase III PIVOTAL trial meets the study™s primary objective
16 Oct 2023 //
GLOBENEWSWIRE
Philogen enters into a Service and Supply Agreement with IBSA for GMP Production
28 Jun 2023 //
GLOBENEWSWIRE
Philogen Announces Clinical Trial Collaboration with MSD
01 Jun 2023 //
GLOBENEWSWIRE
Sun Pharma and Philogen sign licence agreement for anti-cancer therapy
30 May 2023 //
PHARMACEUTICAL TECHNOLOGY
Philogen Publishes New Data on a Fibromun-based treatment
25 May 2023 //
GLOBENEWSWIRE
Philogen Announces Publication of Study in Collaboration with Google
28 Mar 2023 //
GLOBENEWSWIRE
Philogen Provides Corporate Update
01 Dec 2022 //
GLOBENEWSWIRE
Philogen enrols 214 patients in the Nidlegy Phase III European clinical trial
25 Jul 2022 //
GLOBENEWSWIRE
Philogen Provides Corporate Update
23 Jun 2022 //
GLOBENEWSWIRE
Philogen to Present at UBS Global Healthcare Conference
05 May 2022 //
GLOBENEWSWIRE
Philogen Reports Full Year 2021 Results and Provides Corporate Update
01 Apr 2022 //
GLOBENEWSWIRE
Philogen gets France ANSM nod to begin new phase II study to evaluate Nidlegy
21 Feb 2022 //
PHARMABIZ
Philogen announces publication of PET clinical data with OncoFAP
07 Jan 2022 //
GLOBENEWSWIRE
PHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN
24 Nov 2021 //
GLOBENEWSWIRE
Philogen Provides Corporate Update
12 Nov 2021 //
GLOBENEWSWIRE
Philogen Announces R&D Program Update
02 Jul 2021 //
GLOBENEWSWIRE
Philogen Announces the Completion of a Second Interim Analysis of Its Phase III
13 Jan 2021 //
PRNEWSWIRE
Philogen Announces Publication of Malignant Brain Tumor Study Results
08 Oct 2020 //
WFMZ
Philogen receives Swissmedic approval to begin phase II study of Nidlegy
29 Jun 2020 //
PHARMABIZ
Philogen Received Clinical Trial Authorisation With Nidlegy
26 Jun 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.